Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Grade 3b Follicular Lymphoma, High-grade B-cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Non-hodgkin Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Conditions
Keywords
Relapsed/Refractory B-cell Lymphoma
Brief summary
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Detailed description
This is a two-part, non-randomized, open label, single-site Phase 1 study of CD79b-19 CAR T cells as a treatment for relapsed/refractory Non-Hodgkin Lymphoma. This study consists of 2 parts: * Part A (Dose Escalation): The investigators are looking to find the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study intervention. The dose given will depend on the number of participants who have been enrolled prior and how well the dose was tolerated. Once determined, this highest dose will then be used in the dose expansion part of the study. * Part B (Expansion Cohort): Participants will be treated at the respective dose as determined during Part A (Dose Escalation). CD79b-19 CAR T cells is an investigational treatment that uses a person's own immune cells, called T cells, to try to kill their cancerous cells. T cells fight infections and can also kill cancer cells in some cases. The U.S. Food and Drug Administration (FDA) has not approved CD79b-19 CAR T cells as a treatment for any disease. This is the first time that CD79b-19 CAR T cells will be given to humans. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Participants will receive one infusion of the study treatment and will be followed for up to 2 years. It is expected that about 24 people will take part in this research study.
Interventions
DRUGCD79b-19 CAR T cells
Intravenous infusion
DRUGCyclophosphamide
Intravenous infusion
DRUGFludarabine
Intravenous infusion
Sponsors
Marcela V. Maus, M.D.,Ph.D.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntarily sign informed consent form(s) * ≥18 years of age at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%, see Appendix A) * Diagnosis of histologically or cytologically confirmed relapsed/refractory (R/R) Non Hodgkins lymphoma as defined as one of the following (Note: only patients with indolent lymphomas that warrant treatment should be treated, this will include those with local symptoms due to progressive/bulky disease, compromised organ function, B symptoms, extra-nodal disease, cytopenias from marrow involvement and/or in the opinion of the treating physician believe that any of the above symptoms or potentially life threatening involvement will occur will be treated): 1. Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a 1\. R/R disease after 2 or more prior lines of systemic therapy 2. Marginal Zone Lymphoma (MZL) nodal of extranodal: 1\. R/R disease after 2 or more prior lines of systemic therapy 3. Diffuse large B-cell lymphoma (DLBCL), including transformed follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL) and grade 3b Follicular Lymphoma (FL). 1. R/R disease after 2 or more prior lines of therapy OR 2. Relapsed following autologous SCT, OR 3. Ineligible for autologous SCT. 4. Mantle cell lymphoma 1. R/R disease as defined by disease progression after last regimen (including autologous SCT) OR 2. Refractory disease as defined as failure to achieve a CR to last regimen. 3. Prior therapy must include: * Anthracycline or bendamustine-containing chemotherapy AND * Anti-CD20 monoclonal antibody therapy AND * BTKi therapy (progression does not have to be documented on BTKi). * Subjects must have measurable disease according to appropriate disease specific criteria. * Adequate absolute lymphocyte count (ALC \> 100 cells/ul) within one week of apheresis. * Adequate bone marrow function defined by absolute neutrophil count (ANC) \>1000 cells/mm3 without growth factor support (filgrastim within 7 days or pegfilgrastim within 14 days) and untransfused platelet count \>50,000 mm3. * Left ventricular ejection fraction \> 40% * Adequate hepatic function defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 × upper limit of normal (ULN) and direct bilirubin \< 1.5 × ULN. * Adequate renal function defined by creatinine clearance \>60 ml/min using the Cockcroft-Gault formula. * The effects of CD79b-19 CAR T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis. Women of childbearing potential are required to use adequate contraception for up to 1 year post CD79b-19 CAR T cell infusion. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and until 6 months after last CD79b-19 CAR T cells administration. * Ability and willingness to adhere to the study visit schedule and all protocol requirements Inclusion Criteria for treatment (Initiating Lymphodepletion/Cell Infusion): * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%, see Appendix A) * No active, uncontrolled, systemic bacterial, viral, or fungal infection. If febrile, the patient must have negative blood cultures x48 hours at time of cell infusion AND on appropriate broad spectrum antibiotic therapy * Oxygen saturation \>92% on room air while awake * No additional anti-cancer therapy since leukapheresis excluding steroids at or below physiologic dosing. Infusion may be delayed by up to 5 days after completion of LD chemo, without sponsor approval, in the event that these issues resolve in that time frame. The above criteria need to be met to start treatment (for both initiation of lymphodepletion and cell infusion).
Exclusion criteria
for Leukapheresis for Parts A and B: * Treatment with an any investigational cellular therapy within 8 weeks prior to apheresis. * Any systemic anti-cancer therapy within 1 weeks or 5 half-lives of leukapheresis, whichever is shortest, excluding steroids (prednisone) at or below physiologic dosing (5mg). * No bispecific T cell engagers within 6 months of leukapheresis. * No bendamustime within 6 months of leukapheresis. * Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above physiologic dosing). Intermittent topical, inhaled, or intranasal corticosteroids are allowed. * Ongoing systemic immunosuppression for acute and/or chronic GVH as a result of previous allogeneic bone marrow transplant and at least 12 weeks out from prior allogeneic SCT. * Presence of active CNS disease * Significant co-morbid condition or disease which in the judgment of the Principal Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, and/or recent significant traumatic injury. * Active, uncontrolled, systemic bacterial, viral, or fungal infection. * Subjects with a history of class III or IV congestive heart failure or with a history of non- ischemic cardiomyopathy. * Subjects with unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the previous 3 months. * Subjects with arterial vascular disease such as history of cerebrovascular accident or peripheral vascular disease requiring therapeutic anti-coagulation. * Subjects with history of a new pulmonary embolism (PE) /deep vein thrombosis (DVT) within 6 months of beginning lymphodepletion requiring ongoing anticoagulation. * Subjects with second malignancies if the second malignancy has required therapy in the last 3 years or is not in complete remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy other than hormonal therapy. * Pregnant or lactating women. Pregnant women are excluded from this study because CAR-79b-19 T cell drug product is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-79b-19 T cell drug product, breastfeeding should be discontinued if the mother is treated with CAR-79b-19 T cell drug product. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events (AEs) | From Day 0 to 2 years post-treatment | Study-related adverse events (AEs) will be listed and tabulated by type and study cohort. The rate of AEs in all infused patients, both within study cohorts and overall, will be calculated and reported with exact 95% confidence intervals. A separate safety analysis will report similar information within patients infused at the target dose of 1x108 or 3x108 CD79b-19 CAR T cells. |
| Incidence of Dose Limiting Toxicity (DLT) | From Day 0 to 2 years post-treatment | Dose-limiting toxicities will be listed and tabulated by type and study cohort. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | 1 month, 6 months, 12 months, and 24 months after CD79b-19 CAR T cells treatment | Data will be listed, tabulated, and presented descriptively using Kaplan Meier plots. |
| Overall Survival (OS) | 1 month, 6 months, 12 months, and 24 months after CD79b-19 CAR T cells treatment | Data will be listed, tabulated, and presented descriptively using Kaplan Meier plots. |
| Progression Free Survival (PFS) | 1 month, 6 months, 12 months, and 24 months after CD79b-19 CAR T cells treatment | Data will be listed, tabulated, and presented descriptively using Kaplan Meier plots. |
Countries
United States
Contacts
CONTACTMatthew Frigault, MD
PRINCIPAL_INVESTIGATORMatthew Frigault, MD
Massachusetts General Hospital
Outcome results
None listed